Skip to main content
Tetra Bio-Pharma Inc. logo

Tetra Bio-Pharma Inc. — Investor Relations & Filings

Ticker · TBPMQ ISIN · CA88166Y1007 LEI · 5299000CYH3P8XC2UO53 TSX Manufacturing
Open in API
Filings indexed 720 across all filing types
Latest filing 2020-03-06 Regulatory Filings
Country CA Canada
Listing TSX TBPMQ

About Tetra Bio-Pharma Inc.

https://tetrabiosciences.com/

Tetra Bio-Pharma is a biopharmaceutical company specializing in the discovery and development of cannabinoid-derived drugs and medicinal plant-based products. The company maintains an advanced pipeline encompassing biopharmaceuticals, natural health, and veterinary products. Clinical programs are focused on therapeutic areas such as inflammation, pain management (including alternatives to opioids), and ophthalmology. Tetra emphasizes rigorous clinical trials and scientific evidence, utilizing novel approaches, unique mechanisms of action, and high-quality delivery methods to address unmet patient needs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2020-03-06 English
Material change report - English.pdf
Regulatory Filings
2020-03-06 English
News release - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a press release announcing the exercise of an over-allotment option in connection with a bought deal financing by Tetra Bio-Pharma. It details the issuance of additional units, the gross proceeds, the terms of the units and warrants, and the intended use of proceeds. There is no financial statement or detailed financial analysis present. The document is clearly an update on a capital raising event, specifically a financing activity. It is not an annual report, earnings release, or any other type of report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content support this classification with high confidence.
2020-03-05 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a co-development agreement between Tetra Bio-Pharma and MAKScientific. It discusses the strategic partnership, research pipeline, and future growth prospects but does not contain any financial statements, regulatory filings, or detailed financial data. There is no indication that this is an earnings release, annual report, or any other formal financial or regulatory filing. The content is primarily an announcement of a business development and partnership agreement. Therefore, the most appropriate classification is a Regulatory Filing (RNS), which serves as a fallback category for general regulatory announcements and miscellaneous filings that do not fit other specific categories.
2020-02-27 English
News release - English.pdf
Regulatory Filings
2020-02-25 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from Tetra Bio-Pharma providing additional information on their drug QIXLEEF following a Letter of Advice and Type B meeting with the US FDA. It discusses clinical trial plans, regulatory guidance, and market expansion for the drug. There are no financial statements, earnings data, or detailed financial analysis present. The content focuses on regulatory and clinical development updates rather than financial results or management commentary. It is not an annual or interim report, earnings release, or investor presentation. The document is an update on regulatory and clinical development progress, which fits best under the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit other more specific categories.
2020-02-24 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.